Abstract
S-(+)-Norfenfluramine (SNF)—an active metabolite of the now-banned anorexigen fenfluramine—has been implicated in the drug's appetite-suppressing actions and its life-threatening cardiovascular side effects. SNF reduces appetite through serotonin 5-HT2C receptor activation; it causes cardiopulmonary side effects through 5-HT2B receptor activation. Thus, we attempted to identify molecular determinants of SNF binding to 5-HT2B receptors distinct from those underlying SNF-5-HT2C/2A receptor interactions. Mutagenesis implicated Val2.53 in SNF binding to 5-HT2B receptors. Ligand docking simulations suggested both Val2.53 γ-methyl groups form stabilizing van der Waals' (vdW) interactions with the α-methyl group of SNF. A V2.53L mutation induced a 17-fold decrease in affinity; molecular dynamics (MD) simulations suggested that this decrease resulted from the loss of one 2.53-α-methyl group vdW interaction. Supporting this, 1) the binding of norfenfluramine (NF) analogs lacking an S-(+) α-methyl group (RNF and α-desmethyl-NF) was less sensitive to the V2.53L mutation, and 2) a V2.53A mutation decreased SNF affinity 190-fold, but decreased RNF and α-desmethyl-NF affinities only 16- and 45-fold, respectively. We next addressed whether the α-methyl group of SNF contributes to 5-HT2C/2A receptor affinity. Removal of the α-methyl group (RNF and α-desmethyl-NF), which reduced 5-HT2B receptor binding 3-fold, did not affect 5-HT2C/2A receptor binding. An α-ethyl substituent (α-ethyl-NF), which decreased 5-HT2B receptor affinity 46-fold, reduced 5-HT2C and 5-HT2A receptor binding by 14- and 5-fold, respectively. Finally, we determined that residue 2.53 affects SNF potency and efficacy at 5-HT2B receptors but not at 5-HT2C and 5-HT2A receptors. In conclusion, vdW interactions between residue 2.53 and the α-methyl group of SNF contribute to the ligand's 5-HT2 receptor subtype-selective pharmacology.
- Received November 12, 2004.
- Accepted April 14, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|